Avalyn Pharma (NASDAQ:AVLN) Upgraded to “Strong-Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Avalyn Pharma (NASDAQ:AVLN) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley assumed coverage on shares of Avalyn Pharma in a research report on Tuesday. They set an “overweight” rating and a $53.00 price target for the company. Evercore assumed coverage on shares of Avalyn Pharma in a research report on Tuesday. They set an “outperform” rating and a $51.00 price target for the company. Guggenheim assumed coverage on shares of Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $80.00 price target for the company. Finally, Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy” and an average price target of $59.00.

Avalyn Pharma Trading Down 7.4%

Shares of AVLN opened at $26.70 on Monday. Avalyn Pharma has a twelve month low of $25.05 and a twelve month high of $32.22.

Insider Buying and Selling

In related news, Director Jill Carroll bought 277,778 shares of the business’s stock in a transaction on Friday, May 1st. The stock was acquired at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the transaction, the director owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 14.55% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the business’s stock in a transaction on Friday, May 1st. The stock was bought at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the transaction, the insider owned 2,186,562 shares in the company, valued at $39,358,116. This trade represents a 34.06% increase in their position. The disclosure for this purchase is available in the SEC filing.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.